Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreens Boots Alliance (WBA) and VillageMD announce the opening of 20 new Village Medical at Walgreens primary care practices in Tampa over the next year. The first location opened on Oct. 26. This expansion follows a similar effort in Orlando, enhancing access to healthcare for Florida residents, particularly those with chronic conditions. The partnership aims to create over 990 jobs and includes a commitment to have 1,000 primary care practices by 2027, with over half located in underserved areas, improving healthcare access and coordination.
Summary not available.
Hims & Hers (NYSE: HIMS) and Walgreens (NASDAQ: WBA) have announced a collaboration to enhance access to health and wellness solutions. Hims & Hers products, including supplements and sexual health offerings, will be available at over 7,000 Walgreens locations and on walgreens.com starting early November. This partnership aims to destigmatize health topics and support Hims & Hers' goal of mass market accessibility, providing trusted health products to consumers in the U.S.
SigmaLedger has announced the adoption of its coupon fraud prevention solution, CuBE, by Procter & Gamble and Walgreens. This innovative system addresses the over $100 million annual losses due to coupon fraud in the retail industry. CuBE uses blockchain technology to validate coupons at the point of sale, effectively eliminating fraudulent transactions in real-time. With its deployment in over 10,000 US stores, CuBE has reportedly reduced coupon fraud by nearly 90%. The product streamlines the coupon clearing process, leading to faster reimbursements for retailers.
Walgreens will start administering Pfizer’s COVID-19 vaccine to children aged 5-11, beginning November 6, following FDA Emergency Use Authorization. With around 45 million COVID-19 vaccinations given by Walgreens thus far, the initiative targets pediatric health, especially in areas with high Social Vulnerability Index scores. The vaccine boasts a 90% efficacy rate, and appointments can be scheduled online or via phone, accommodating family schedules. This step is pivotal for preventing severe illness in children during the upcoming holiday season.
Western Dental & Orthodontics, in collaboration with the NFL Alumni Association-Southern California Chapter and Walgreens, will host a free COVID vaccination event on October 30 from 11 am to 3 pm in Inglewood, CA. The event aims to promote COVID awareness and provide free vaccinations and flu shots to attendees aged 12 and older. Families can also enjoy Halloween-themed activities. Walgreens pharmacists will administer the vaccines free of charge, contributing to community health during the pandemic.
Walgreens (WBA) has expanded COVID-19 booster shot eligibility, now offering Moderna and Johnson & Johnson vaccines nationwide following FDA and CDC guidelines. As of September 24, Pfizer booster doses were also authorized. Eligible individuals include seniors, long-term care residents, and those with underlying health conditions. Despite increasing vaccination rates among Hispanic and Black adults, disparities persist. Walgreens aims to address vaccine hesitancy through community-focused initiatives, having administered nearly 60% of COVID vaccines to people of color. Appointments can be scheduled online or via phone.
Walgreens Boots Alliance (WBA) has declared a quarterly dividend of 47.75 cents per share, maintaining the previous quarter's rate and marking a 2.1% increase from last year. The dividend will be payable on December 10, 2021, to shareholders of record as of November 15, 2021. WBA has paid dividends for 356 consecutive quarters and has increased the dividend for 46 consecutive years. This commitment reflects the company’s stability and confidence in its financial outlook.
Walgreens has launched the Flu Index® for the 2021-2022 season, showing a 23% increase in flu activity nationwide compared to last season. This index, now in its eighth year, aims to help communities track flu activity and encourage vaccinations. Las Vegas and Texas markets lead in flu activity due to heightened interactions as COVID restrictions ease. The CDC advises vaccination by the end of October. The index highlights disparities in flu vaccination rates among Black and Hispanic communities, prompting Walgreens to enhance outreach efforts for underserved populations.
Walgreens Boots Alliance (WBA) has launched Walgreens Health, a new consumer-focused healthcare strategy, supported by majority investments in VillageMD and CareCentrix. This initiative aims to enhance primary care and home care services, improving health outcomes and reducing costs. Key objectives include transforming core operations, optimizing capital allocation, and building a high-performance culture. The company anticipates 4% adjusted EPS growth over the next three years, with a flat growth prediction for fiscal 2022. WBA's investments in VillageMD and CareCentrix total $1.19 billion, expanding its presence in the healthcare market.